Sionna Therapeutics is trading 5.02% down now at $4.16, likely weighed down by broader market pressure after September inflation exceeded forecasts. - Higher inflation lifted Treasury yields and expectations for a possible Federal Reserve rate hike, pressuring growth-oriented shares, including biotech. - No company-specific announcement dated October 14 appears in Sionna Therapeutics’ latest news releases; its latest listed update is dated October 8.